# US 2026/0242398 A1 · Benzopyrimidin-4(3h)-ones as pi3k inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0242398 A1
- Document ID: US20260242398A1
- Status: Published application
- Kind: A1
- Application number: 18/871,390
- Filed: 2023-06-06
- Published: 2026-08-20
- Earliest claimed: 2022-06-08
- Assignees: OnKure, Inc.
- Applicants: OnKure, Inc.
- Inventors: James F. Blake; Mark Laurence Boys; David A. Mareska; Joshua Nathaniel Payette; Christie A. Schulte; Bryan Yestrepsky; Qian Zhao
- Web page: https://patentgrep.com/patent/US20260242398A1

## CPC

- C07F 7/0816: {said ring comprising Si as a ring atom}
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/695: Silicon compounds
- A61P 35/00: Antineoplastic agents
- C07D 239/88: Oxygen atoms
- C07D 239/90: with acyclic radicals attached in position 2 or 3
- C07D 239/96: Two oxygen atoms
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Novel PI3K inhibitors of the general Formula (1) are described along with methods of their preparation and their use in the treatment of diseases associated with the elevation or activation of the PI3K pathway, wherein R1 to R8 are as defined.

## Claims

### Claim at position 1

-37. (canceled)

### Claim 38

A compound of Formula (1)
or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound,
or a pharmaceutically acceptable salt thereof,
wherein:
R1 is H, C1-C4 alkyl or C3-C7 cycloalkyl;
each R2 is independently H, C1-C4 alkyl, C3-C7 cycloalkyl, R14—C≡C—, halogen, CN, CF3, OCF3, CFH2 or CF2H;
R3 is H, C1-C4 alkyl, C3-C7 cycloalkyl, CF3, CFH2 or CF2H, and where R3 is not H, the carbon atom attached to R3 is a chiral center and exists as a (R)- and (S)-racemic mixture or as either the (R)- or (S)-enantiomer;
R4 is H or C1-C4 alkyl;
R6 is H, C1-C4 alkyl, C3-C7 cycloalkyl, heteroaryl, CF3, CFH2 or CF2H;
R7 is H, C1-C4 alkyl, C3-C7 cycloalkyl, halogen, CN, CF3, OCF3, OCH3, CFH2 or CF2H;
R8 is H, C1-C4 alkyl, C3-C7 cycloalkyl, halogen, CN, CF3, OCF3, OCH3, CFH2 or CF2H;
R5 is
wherein:
each of L1, L2, L3, L6 and L7 is independently (CHR11), (CHR11—O), (CHR11—S), (C3-C7 cycloalkyl) or a bond;
L4 is C═O, C═S or a bond;
L5 is NR10, S, O or a bond;
R9 is H, C(═O)R12, C(═O)NR12R13, C(═O)OR12, C1-C6 alkyl, C1-C6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C1-C6 alkyl, C1-C6 fluoroalkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted, or alternatively when NR10 is present, R9 and R10 together with the attached nitrogen atom may form a 4-7 membered non-aromatic heterocyclic ring, where the ring may contain additional heteroatoms and is substituted or unsubstituted;
each of R10 and R11 is H or C1-C4 alkyl, where the C1-C4 alkyl is unsubstituted or substituted; and
each of R12 and R13 is independently H or C1-C6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, where each of the C1-C6 alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl is unsubstituted or substituted or alternatively, R12 and R13 together with the attached nitrogen atom together with the attached nitrogen atom may form a 4-7 membered non-aromatic heterocyclic ring, where the ring may contain additional heteroatoms and is substituted or unsubstituted;
each R14 is independently H, C1-C3 alkyl or C3-C7 cycloalkyl;
or R5 is
a non-aromatic N-linked heterocyclic ring
where the heterocyclic ring is substituted or unsubstituted, optionally contains one or more additional atoms selected from N (where the N is substituted or unsubstituted), O, Si (where the Si is substituted or unsubstituted) and S (where the S is oxidized or unoxidized), and is optionally part of a bridged, fused or spiro ring system.

### Claim 39 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R5 is —(NR10)-L1-L2-L3-L4-L5-L6-L7-R9, where L1 to L7, R9 and R10 are as defined.

### Claim 40 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R5 is —O-L1-L2-L3-L4-L5-L6-L7-R9, where L1 to L7 and R9 are as defined.

### Claim 41 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R5 is —S-L1-L2-L3-L4-L5-L6-L7-R9; —S(O)-L1-L2-L3-L5-L6-L7-R9; or —S(O)2-L1- L2-L3-L5-L6-L7-R9, where L1 to L7 and R9 are as defined.

### Claim 42 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R5 is a N-linked non-aromatic heterocyclic ring
where the heterocyclic ring is substituted or unsubstituted, optionally contains one or more additional atoms selected from N (where the N is substituted or unsubstituted), O, Si (where the Si is substituted or unsubstituted) and S (where the S is oxidized or unoxidized), and is optionally part of a bridged, fused or spiro ring system.

### Claim 43 (depends on 42)

The compound according to claim 42 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein the heterocyclic ring is substituted or unsubstituted, optionally contains one or more additional heteroatoms selected from N, O, Si and S, and is not part of a bridged, fused or spiro ring system.

### Claim 44 (depends on 42)

The compound according to claim 42 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein the heterocyclic ring is substituted or unsubstituted, optionally contains one or more additional heteroatoms selected from N, O, Si and S, and is part of a bridged, fused or spiro ring system.

### Claim 45 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R1 is H.

### Claim 46 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein each R2 is H.

### Claim 47 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R3 is CH3.

### Claim 48 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R4 is H.

### Claim 49 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R6 is CH3.

### Claim 50 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R7 is CH3 or F.

### Claim 51 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R8 is H.

### Claim 52 (depends on 38)

The compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R1, each R2 and R4 are H.

### Claim 53 (depends on 38)

The compound according to claim 38, wherein the compound of Formula (1) is the compound of Formula (2)
or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof, wherein R3 is CH3, CF3, CFH2 or CF2H; R5 is defined as in the compound of Formula (1); R7 is CH3 or F; and the carbon marked with * is a chiral center and exists as a (R)- and (S)-racemic mixture or as either (R)- or (S)-enantiomer.

### Claim 54 (depends on 38)

A pharmaceutical composition comprising the compound of claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

### Claim 55 (depends on 54)

The pharmaceutical composition according to claim 54, further comprising one or more anti-cancer agents.

### Claim 56 (depends on 55)

The pharmaceutical composition according to claim 55, wherein the one or more anti-cancer agents are selected from cyclophosphamide, dacarbazine, cisplatin, methotrexate, mercaptopurine, thioguanine, fluorouracil, cytarabine, vinblastine, paclitaxel, doxorubicin, bleomycin, mitomycin, prednisone, tamoxifen, flutamide, asparaginase, rituximab, trastuzumab, imatinib, retinoic acid, amifostine, camptothecin, topotecan, thalidomide, lenalidomide and a proteasome inhibitor.

### Claim 57 (depends on 38)

A method of treating a disease in which PI3K activity is implicated in a subject in need of such treatment, the method comprising administering to the subject a therapeutically effective amount of the compound according to claim 38 or a solvate, enantiomer, diastereomer, tautomer, polymorph or isotope-labeled compound, or a pharmaceutically acceptable salt thereof.
